Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer

被引：67

作者：

Conibear, John ^{[1
]}

Chia, Brendan ^{[1
]}

Ngai, Yenting ^{[2
]}

Bates, Andrew Tom ^{[3
]}

Counsell, Nicholas ^{[2
]}

Patel, Rushil ^{[4
]}

Eaton, David ^{[4
]}

Faivre-Finn, Corinne ^{[5
,6
]}

Fenwick, John ^{[7
]}

Forster, Martin ^{[8
]}

Hanna, Gerard G. ^{[9
]}

Harden, Susan ^{[10
]}

Mayles, Philip ^{[11
]}

Moinuddin, Syed ^{[8
]}

Landau, David ^{[12
,13
]}

机构：

[1] St Bartholomews Hosp, London, England

[2] Canc Res UK & UCL Canc Trials Ctr, London, England

[3] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England

[4] Mt Vernon Hosp, Natl Radiotherapy Trials QA Grp RTTQA, Northwood, Middx, England

[5] Univ Manchester, Manchester, Lancs, England

[6] Christie NHS Fdn Trust, Manchester, Lancs, England

[7] Univ Oxford, Dept Oncol, Oxford, England

[8] Univ Coll London Hosp, London, England

[9] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland

[10] Addenbrookes Hosp, Cambridge, England

[11] Clatterbridge Canc Ctr, Liverpool, Merseyside, England

[12] Guys & St Thomas NHS Trust, London, England

[13] UCL, Dept Oncol, London, England

来源：

BMJ OPEN | 2018年 / 8卷 / 04期

关键词：

BODY RADIATION-THERAPY; I/II TRIAL; METASTASES; SURVIVAL; QLQ-C30; TUMORS; SITES; SBRT;

D O I：

10.1136/bmjopen-2017-020690

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction Following growing evidence to support the safety, local control (LC) and potential improvement in overall survival (OS) in patients with oligometastatic non-small cell lung cancer (NSCLC) that have been treated with local ablative therapy such as stereotactic ablative radiotherapy (SABR) and stereotactic radiosurgery (SRS), we initiate the SARON trial to investigate the impact and feasibility of adding SABR/SRS and radical radiotherapy (RRT) following standard chemotherapy on OS. Methods and analysis SARON is a large, randomised controlled, multicentre, phase III trial for patients with oligometastatic EGFR, ALK and ROS1 mutation negative NSCLC (1-3 sites of synchronous metastatic disease, one of which must be extracranial). 340 patients will be recruited over 3 years from approximately 30 UK sites and randomised to receive either standard platinum-doublet chemotherapy only (control arm) or standard chemotherapy followed by RRT/SABR to their primary tumour and then SABR/SRS to all other metastatic sites (investigational arm). The primary endpoint is OS; the study is powered to detect an improvement in median survival from 9.9 months in the control arm to 14.3 months in the investigational arm with 85% power and two-sided 5% significance level. The secondary endpoints are LC, progression-free survival, new distant metastasisfree survival, toxicity and quality of life. An early feasibility review will take place after 50 randomised patients. Patients requiring both conventional thoracic RT to the primary and SABR to a thoracic metastasis will be included in a thoracic SABR safety substudy to assess toxicity and planning issues in this subgroup of patients more thoroughly. Ethics and dissemination All participants are given a SARON patient information sheet and required to give written informed consent. Results will be submitted for presentation at local and international conferences and expected to be published in a peer-reviewed journal.

引用

页数：10

共 35 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].